STON1

Across TCGA pan-cancer cohorts, STON1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated STON1 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher STON1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated STON1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

GBM, UCEC, and PDAC are the cancer types where STON1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Quartile	All	0.747	1.000	.001	8	view →
UCEC	OS	Median	II,III,IV	0.620	1.000	.011	6	view →
PDAC	DFS	Median	II,III,IV	0.465	0.721	.025	4	view →
LUAD	DFS	Quartile	All	0.783	0.436	.017	3	view →
CCRCC	OS	Quartile	II,III,IV	1.000	0.671	.039	2	view →
LSCC	DFS	Median	All	0.498	0.828	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

STON1–GBM (OS)

Open the GBM breakdown →